Acarix Recognized with Global Digital Innovation Award
Acarix Achieves Prestigious Global Recognition
Acarix, a frontrunner in AI and acoustics for cardiac diagnostics, proudly announces its recent distinction at the Global Cardiovascular Awards. The company has secured the 2025 Digital Innovation Award, alongside an esteemed honorable mention for Innovation in Cardiac Imaging for its groundbreaking CADScor® System.
Revolutionizing Cardiac Diagnostics
The Digital Innovation Award celebrates pioneering initiatives in digital, mobile, and AI technologies that enhance cardiovascular care. Acarix’s CADScor System is transforming early diagnostics with a non-invasive, AI-driven approach, allowing quick and precise assessments for coronary artery disease (CAD). This innovation empowers healthcare providers to efficiently identify patients whose stable chest pain necessitates further evaluation.
Comments from Leadership
Aamir Mahmood, the President and CEO of Acarix, expressed gratitude for this recognition, stating, "It's an honor to be celebrated alongside innovators shaping cardiovascular care globally. This award acknowledges our dedication to merging advanced AI and acoustic technology to improve outcomes for patients. The CADScor System enables clinicians to ascertain low-risk patients with over 96% accuracy, significantly minimizing unnecessary procedures and enhancing streamlined patient care pathways, representing a critical advancement for both patients and healthcare providers."
Expert Evaluation at the Global Cardiovascular Awards
The Global Cardiovascular Awards feature a panel of esteemed leaders, including clinical experts and CEOs, who conduct thorough evaluations of innovations demonstrating a tangible impact on cardiovascular health worldwide. The distinction of being selected as a winner is a testament to the meaningful contributions made by Acarix in advancing prevention, diagnosis, and treatment within the realm of cardiovascular medicine.
The Legacy of the Global Cardiovascular Awards
These awards aim to shine a spotlight on visionaries influencing the future of cardiovascular treatment and diagnosis. Acarix is among an elite group recognized for exceptional contributions, reinforcing the collaborative effort to combat cardiovascular diseases through innovation and commitment.
About Acarix and Its Innovative Solutions
Acarix is a pioneering Swedish medical device company at the forefront of providing inventive solutions for early coronary artery disease risk assessments right at the point of care. The CE-marked and FDA De Novo-cleared CADScor® System is tailored for patients presenting with chest pain, effectively distancing them from unnecessary, invasive, and costly diagnostic paths. This system has already been utilized in over 40,000 patients, employing highly sensitive acoustic detection along with advanced computational analysis to assess coronary blood flow and conclusively rule out significant CAD, achieving high certainty.
Market Presence and Future Prospects
Listed on the Nasdaq First North Premier Growth Market in Stockholm with the ticker ACARIX, Acarix also engages in cross-trading on the OTCQB market in the U.S. under the ticker ACIXF. The company’s dedication to advancing cardiac diagnostics is supported by Carnegie Investment Bank, serving as its Certified Advisor.
Stay Connected with Acarix
To learn more about their innovative solutions, visit www.acarix.com.
Media Contact Information
For media inquiries, connect with Ashley Wilson at +1 405 413 5201 or reach out via email at awilson@saxum.com.
Frequently Asked Questions
What is the CADScor System?
The CADScor System is a pioneering diagnostic tool that uses AI and acoustic technology to assess coronary artery disease risk non-invasively.
What recognition did Acarix receive recently?
Acarix was awarded the 2025 Digital Innovation Award and earned an honorable mention for Innovation in Cardiac Imaging at the Global Cardiovascular Awards.
Who leads Acarix?
The company is led by President and CEO Aamir Mahmood, who emphasizes their commitment to enhancing patient care through innovation.
How does the CADScor System work?
It combines highly sensitive acoustic detection with advanced computational analysis to provide accurate risk assessments for chest pain patients.
Where can I find more information about Acarix?
Add your interest and explore Acarix's innovations on their official website at www.acarix.com.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.